NERM
NKTR icon

New England Research & Management’s Nektar Therapeutics NKTR Stock Holding History

New England Research & Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-740
Closed -$395K – 178
2019
Q2 		$395K Buy
740
+16
+2% +$8.02K 0.27% 121
2019
Q1 		$365K Buy
+724
New +$429K 0.25% 121

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New England Research & Management's NKTR Position: Q3 2019 in Review

New England Research & Management sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 740 shares — an estimated $395K sold.

New England Research & Management first reported a position in NKTR in Q1 2019 and held it in 2 quarters. The position peaked at $395K in Q2 2019. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • New England Research & Management reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • New England Research & Management sold 740 Nektar Therapeutics shares in Q3 2019, an estimated $395K.
  • New England Research & Management first reported a position in Nektar Therapeutics in Q1 2019 and held it in 2 quarters.
  • New England Research & Management's Nektar Therapeutics position peaked at $395K in Q2 2019.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on New England Research & Management's 13F filing for Q3 2019, filed 4 Nov 2019.